Background: Evolving immune-mediated therapeutic strategies for rheumatoid arthritis (RA) may benefit from an improved understanding of the complex role that T-cell activation plays in RA. This study assessed the potential of fluorine-18-labeled 9-b-Darabinofuranosylguanine ([
Introduction
Molecular imaging methods play a pivotal role in gaining a better understanding of the immunologic evolution of rheumatoid arthritis (RA) and will likely be critical to patient selection for and clinical monitoring of immune-based therapies for RA in the future. The complex roles that T cells and T-cell activation play in the development and progression of RA are not fully understood but appear to be related to the presence of autoreactive T cells (CD4 þ T cell) and impaired regulatory T cells. [1] [2] [3] [4] Following infiltration of T cells into joints, cytokine and other cell signaling molecule levels increase and create an inflammatory environment that manifests in destruction of the synovial cartilage and bone with sustained autoimmunity enabled by memory T cells and T-effector cells. [5] [6] [7] [8] [9] Understanding the relationship between T cells and the progression of RA has been instrumental in expanding the number of potential RA therapies. 10, 11 Rituximab, a monoclonal antibody directed against the CD20 antigen, has been used for many years in the treatment of RA in the approximate 40% of patients who do not respond to methotrexate, but its indirect role in T-cell depletion in peripheral blood in responders was only appreciated more recently. [12] [13] [14] Newer therapies specifically target T cells or mediators of T-cell activation. 15, 16 Cytotoxic T-lymphocyte-associated antigen 4 IgG1 (CTLA4Ig) is a costimulation blocker that binds to CD80 and CD86 on antigenpresenting cells, preventing their ability to bind CD28 and thereby activate T cells. 17 Rheumatoid arthritis therapeutics with other immune-modulating targets, such as antibodies to tumor necrosis factor alpha, have demonstrated the ability to decrease radiographic progression of RA. 18 These newer therapeutic targets have complex and variable effects on T-cell activation, and current therapeutics aimed at any one of these targets have varying interactions with the inflammatory environment, highlighting the urgency to develop tools to both investigate relationships of immune-modulating networks in vivo and monitor the immune-based effects of therapy in patients. [19] [20] [21] [22] [23] [24] [25] [26] In vivo positron emission tomography (PET) imaging has been utilized to explore various points of the immune-mediated pathways targeted by new immunotherapeutics. Imaging targets have included PD-1/PD-L1, translocator protein, CD8
þ T cells, T cell receptor (TCR)-transgenic T cells, and others. [27] [28] [29] [30] [31] [32] [33] A minority of these approaches has been translated into humans. 34 All aforementioned approaches are limited to directly labeling T cells or tracking TCR-transgenic T cells or T cells altered genetically or otherwise. Direct imaging of native T cells recruited in response to anti-CTLA-4 immunotherapy in a murine tumor xenograft model of colon cancer using the CD3 PET imaging agent [
89 Zr]-p-isothiocyanatobenzyl-deferoxamine-CD3 was only demonstrated recently by Larimer et al. 35 An approach to native T-cell imaging that differentiates activated from nonactivated cells to further characterize the evolution of the immune response would significantly advance the utility of PET-based imaging of T cells and its use in evaluating inflammatory activity in diseases such as RA both before and following treatment.
Fluorine 36, 37 The aim of this feasibility study was to evaluate [ 18 F]F-AraG imaging as a means to selectively and noninvasively assess the presence of an activated immune environment in the affected joint of an immunemediated small animal model of arthritis, previously shown histologically to involve a mechanism of T-cell infiltration and activation.
Materials and Methods
All experiments involving animals were performed with approval of and oversight by the Institutional Animal Care and Use Committee.
Chemicals and Antibodies
Unless otherwise noted, all supplies were purchased from Sigma Aldrich (St Louis, Missouri). Fluorophoreconjugated antibodies (all purchased from BDPharmingen, San Diego, California) to the following murine marker epitopes (fluor and clone) were acquired: anti-CD3e (PE Cy7, 145-2C11), anti-CD4 (APC Cy7, GK1.5), anti-CD8 (Alexa 700, 53-6.7), anti-CD11b (APC Cy7, M1/70), anti-CD11c (PE Cy7, HL3), anti-CD19 (PE Cy7, 1D3), anti-CD44 (FITC, 1M7), anti-CD45.2 (V500, 104), anti-CD62 L (APC, MEL-14), anti-CD69 (PE, H1.2F3), anti-CD80 (FITC,16-10A1), and anti-CD86 (PE, GL1). Anti-F4/80 (e450, F4/80) was purchased from eBioscience (San Diego, California), and anti-CD25 (PE D594, PC61) was purchased from Biolegend (San Diego, California). 18 ]F-AraG in radiochemical purities of greater than 95% (HPLC analysis) with specific activities ranging from 3 to 8 Ci/mmol (111-296 GBq/mmol) and decay-corrected radiochemical yields of 2% to 5% (total synthesis time 95 minutes). 
Preparation of the Adjuvant-Induced Arthritis Animal Model

Histopathology
Both a control and an inflamed paw were dissected, fixed, decalcified with Kristensen solution, embedded in paraffin, and sliced with a microtome for staining with hematoxylin-eosin for subsequent qualitative histologic analysis.
Flow Cytometry Analysis
Nonimaged AIA models were sacrificed at 6 (n ¼ 4) and 20 (n ¼ 4) days following model preparation. Each AP and CP was minced, as were all lymph nodes from AP and CP draining regions and spleens from 1 mouse each at the 6-and 20-day time points. All tissues were placed in a digestive mixture containing DNAse, fraction 4 low tryptinase collagenase (Worthington Biochemical Corp, Lakewood, New Jersey), magnesium acetate, and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer in Roswell Park Memorial Institute (RPMI)1640 medium supplemented with 5% calf serum for 1 hour at 37 C, after which 1/ 10th volume 0.5 M EDTA was added and cells were strained to remove conglomerates. Following filtration and removal of red cells by ammonium chloride buffer lysis, cells were washed and suspended in phosphate-buffered saline (PBS). Dead cell discrimination was achieved by staining the cells with violet amine reactive dye (Thermo Fisher, Carlsbad, California). Cells were washed once with PBS supplemented with 1% FBS and resuspended in PBS: FBS for every 1 Â 10 6 cells for 15 minutes. Nonspecific antibody binding sites were preblocked with 2 mL anti-CD16/32 and 0.5 mL hamster IgG for 15 minutes on ice. The cells were washed and passed through a 35-micron nylon mesh and divided into 200 mL aliquots, each containing approximately 1 Â 10 5 cells to which was added fluorconjugated antibody (0.1-0.3 mg) for 20 minutes on ice. Cells were then washed, resuspended in PBS: FBS with 1% paraformaldehyde and events acquired on a 4 laser (407, 488, 561, 633 nm) FACSAria III flow cytometer (BD Biosciences, Palo Alto, California). Single stained and unstained controls were used to define sorting gates and to adjust fluorescence compensation. FlowJo software (Treestar, Palo Alto, California) was used postacquisition to adjust fluorescence compensation and set gating.
Lymphocytes and monocyte/macrophages were gated using FSC and SSC scatter plots. Events that excluded the violet dye and were CD45.2 positive were considered live tissue-resident leukocytes and analyzed for further expression of T, B, or macrophage markers. CD3 expression was used to identify T cells, CD19 expression to identify B cells. Macrophages were gated as CD11b-positive and CD11c-negative cells. T, B, and macrophage subsets were then further analyzed for the expression of markers in their antibody staining panels.
T, B, and macrophage subpopulations and their activation status were determined by cytometry using the following antibody combinations:
CD4
þ and CD8 þ T cells: antibodies to CD3, CD4, CD8, CD69, CD62 L, CD44, and CD25. B cells: antibodies to CD19, CD69, and CD80. Macrophages: antibodies to CD11b, CD11c, F4/80, CD80, and CD86.
Results
Imaging
Images demonstrated a visually detectable signal difference between the AP and CP in each animal, with Figure 1 demonstrating representative imaging from an animal. Compared to the CP, the AP in the AIA model demonstrated 7-to 9.5-fold greater signal in the acute phase (6-day postarthritis induction) and 1.5-to 4.5-fold greater signal in the chronic phase (20-day postarthritis induction; Figure 2 ).
Flow Cytometry
No significant differences were found between the percentages of counted cells that were CD4 or CD8-positive T-lymphocytes (gated as live CD45
þ cells) between the CPs and APs or between the 2 time points. The percentage of lymphocytes that were T cells remained constant between the 2 time points for the APs, whereas it decreased significantly between the early and late time points for the CPs (P < .001). The percentage of T cells that were CD4 þ or CD8 þ did not differ between CPs versus APs at either of the time points. Figure 3A provides an overview of the differences in cell markers of T-cell activation between CP and AP at the time points studied. T-cell expression of CD25 differed significantly between AP and CP paws at 6 days (P < .05) but not at the 20-day time point. CD44 did not differ significantly between AP and CP paws at either time point. The percentage of CD4 þ T cells that were CD69 þ were significantly greater in the AP when compared to CP at the earlier time point (P < .01), but there was no significant difference found at the later time point. A higher percentage of CD4 þ cells from the APs were CD69 þ at the earlier time point (P < .001; Figure 3A ). No significant difference was found between the APs and CPs in the percentage of CD8 þ T cells that were CD69 þ ; however, CD69 positivity of CD8 þ cells decreased between the early and late time points (P < .01 for AP; P < .01 for CP; Figure 3A ). CD69 mean fluorescence did not differ between CD4 þ or CD8 þ control and APs at either time point or within either treatment group between time points. Figure  3B provides an overview of the differences in CD62 L expressed by T cells as they go into memory phase, prior to homing to lymph nodes, indicating deactivation. Ki67 staining demonstrated greater activity of CD8 þ T-effector cells in APs when compared to CPs (Figure 4) . Figure 3C provides an overview of the differences in cell markers of B-cell activation between CP and AP at the time points studied. The percentage of CD19 þ B cells, indicating facilitated B-cell receptor signaling, were significantly greater in the AP when compared to CP (P < .05) at the earlier time point. B cells from APs demonstrated a significantly higher mean fluorescence and a higher percentage of CD80 positivity (P < .001), essential for autoreactive T-cell activation, at the earlier time point versus the later time point (Figure 3C ).
Indicators of T-Cell Activation
Indicators of B-Cell Activation
Indicators of Macrophage Activity
There was no significant difference in percentage of CD11b þ macrophages between CPs and APs. However, in both groups, the percentages decreased significantly between the early and late time points (P < .01 for controls, P < .01 for affected). Macrophage CD80 expression did not differ between AP and CP paws.
Lymph Nodes
A single lymph node was taken from the nodal basin draining the CP and AP in each animal, and all cells from each of the respective groups were combined into a single sample for flow cytometry. Trends in the relative CD expression levels of cells from draining nodal basins matched findings in the primary site.
Histology
Microscopy with hematoxylin-eosin stain (Â200) demonstrated inflammatory cell infiltrate in cartilage of APs but not CPs ( Figure 5 ).
Discussion
The aim of this feasibility study was to provide initial assessment of the ability of [
18 F]F-AraG to report the in vivo presence of an activated T-cell environment in an animal model of inflammatory arthritis using noninvasive PET imaging. A PET approach to native T-cell imaging that differentiates activated from nonactivated cells to further characterize the evolution of the immune response would significantly advance the utility of PET-based imaging of T cells and its use in evaluating inflammatory activity in diseases such as RA both before and following treatment.
The AIA animal model of inflammatory arthritis was used whereby CFA was administered into the paw of mice at the level of the ankle. Freund's complete adjuvant is an emulsion made by combining paraffin oil containing the surfactant mannide monooleate with an aqueous suspension of heat-killed mycobacteria that serves as the antigen. Freund's complete adjuvant generally produces transient activation and proliferation of CD4 þ T cells. The mycobacterial antigenic components of CFA provide signal inducing T cells to assume a Th1 profile, manifesting in a robust delayed-type hypersensitivity reaction. Freund's complete adjuvant induces arthritis in animal models characterized by an acute phase of inflammation around the joint, followed by a chronic phase that involves bone. This chronic arthritis is CD4 þ T-cell dependent, possibly mediated by cross reaction of host T cells with mycobacterial heat shock protein (HSP) epitopes and the host's own HSP. Freund's complete adjuvant also generates cytokines and other signals that change rates of leukocyte proliferation and differentiation, providing an overall prolongation of the immune response.
38
[ 18 F]F-AraG PET imaging in this study demonstrated specific uptake within the AIA-injected paw (AP) when compared to the CP in the same animal at both early and late time points. This specific uptake corresponded to the presence of T-cell and B-cell epitopes indicative of T-cell activation and evidence of greater CD8
þ T-effector cell activity rather than any significant difference in cell fractions of lymphocytes. The pattern of markers of T-cell activation in the AP was reflected in the lymph node region draining the AP.
Although Ki67 staining provided evidence of proliferation of CD8 þ T cells in the AP but did not demonstrate CD4 þ T-cell proliferation, the complementarity of measures of proliferation and flow cytometry analyses of activation antigens is well documented. 39 In this study, the combination of these assays further supported the presence of an active cell-mediated immune response occurring within the AP, as indicated on The study was limited to imaging at 2 discrete time points, one chosen to reflect the molecular and cellular characteristics of "acute" inflammation and the other chosen to represent the "chronic" inflammatory environment. The rate of immunemediated response will naturally vary between animals, and the exact constituents of the immune response likely depends somewhat on the exact site of adjuvant injection. The make-up of the cellular response at the given time points cannot, therefore, be precisely predicted and did vary across animals. Therefore, it was not surprising that not all markers of T-cell activation were significantly higher on flow cytometry analysis of cells from the joints and lymph nodes from AIA-affected paws when compared to control. Different stimuli have been shown to produce variations in the percentages of CD4 þ and CD8 þ T cells expressing any given activation antigen, with the variation mediated by a complex network of cytokine signals, the levels of which are also highly dependent on the stimuli and observation timing. [38] [39] [40] [41] An additional limitation of the study was the requirement to perform imaging on a cohort of animals in which AIA was induced in a similar manner at the same time point as the animals whose tissues underwent cellular analysis. In the case of radiolabeled nucleobase analogs, such as 1- (2 The ability to characterize the temporal and spatial evolution of inflammatory arthritis in vivo will allow improved understanding of the similarities and differences in the development of RA in patients with various genetic mutations contributing to their RA as well as the relationship of RA development with other factors such as the external environment. [43] [44] [45] By detecting active inflammation in the joints or elsewhere early in patients known to be at risk for the development of RA, treatment may be able to be initiated earlier, even prior to clinical onset of disease. 46, 47 well as to monitor immune-mediated therapies for RA in clinical trials.
Conclusion
